Due to health issues, this site is no longer maintained and will be shut down shortly.


BeiGene Ltd is a clinical-stage biopharmaceutical company engaged in the discovery & development of molecularly targeted & immuno-oncology drugs for the treatment of cancer. Its product includes BGB-3111, BGB-283 and BGB-290 and one immuno-oncology agent. This is an ADR of a company whose stock trades outside of the U.S. as the symbol HK:6160.

$222.75  +3.04 (1.38%)
As of 03/27/2023 11:31:52 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Large cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  China
Country of incorporation:  
IPO date:  02/03/2016
Outstanding shares:  104,315,230
Average volume:  277,594
Market cap:   $22,847,121,675
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BYYWPW6
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy